Sudhir Srivastava is chief of the Cancer Biomarkers Research Group of the Division of Cancer Prevention at the United States NCI.[1][2] Srivastava has held this position since 2000. He is a co-author of the Bethesda Guidelines for the diagnosis of Hereditary non-polyposis colorectal cancer (HNPCC).[1]
Sudhir Srivastava | |
|---|---|
| Occupation | Scientist |
Srivastava is an elected member of the American Joint Committee on Cancer (AJCC), responsible for developing cancer staging criteria, and serves on the AJCC Executive Committee and the All Ireland-NCI Consortium.[3] Srivastava is a founding member of HUPO, participated in the Plasma Proteome and the Liver Proteome Projects, and supported several HUPO-supported initiatives.[4]
References
edit- ^ a b "Division of Cancer Prevention Staff: Sudhir Srivastava". Archived from the original on 26 June 2013.
- ^ "Cancer Biomarkers Research Group". Archived from the original on 8 October 2012.
- ^ "All Ireland-NCI Consortium".
- ^ "HUPO-supported initiatives". Archived from the original on 15 April 2013.